Propensity-score-based priors for Bayesian augmented control design.
Drug developers are required to demonstrate substantial evidence of effectiveness through the conduct of adequate and well-controlled (A&WC) studies to obtain marketing approval of their medicine. What constitutes A&WC is interpreted as the conduct of randomized controlled trials (RCTs). However, these trials are sometimes unfeasible because of their size, duration, and cost. One way to reduce sample size is to leverage information on the control through a prior. One consideration when forming data-driven prior is the consistency of the external and the current data. It is essential to make this process less susceptible to choosing information that only helps improve the chances toward making an effectiveness claim. For this purpose, propensity score methods are employed for two reasons: (1) it gives the probability of a patient to be in the trial, and (2) it minimizes selection bias by pairing together treatment and control within the trial and control subjects in the external data that are similar in terms of their pretreatment characteristics. Two matching schemes based on propensity scores, estimated through generalized boosted methods, are applied to a real example with the objective of using external data to perform Bayesian augmented control in a trial where the allocation is disproportionate. The simulation results show that the data augmentation process prevents prior and data conflict and improves the precision of the estimator of the average treatment effect.